# Penumbra Inc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Penumbra Inc). ## Overview Penumbra is a U.S.-based medical device company focused on thrombectomy and related interventional therapies for removing blood clots from the body. Its portfolio spans products used in ischemic stroke, pulmonary embolism, acute limb ischemia, embolization, and vascular access, and it sells through direct commercial teams and distributors across the United States and international markets. ## Products & services • Thrombectomy systems for clot removal • Computer assisted vacuum thrombectomy (CAVT) • Neurovascular stroke intervention products • Venous thromboembolism and pulmonary embolism devices • Acute limb ischemia treatment products • Embolization and vascular access technologies - **Thrombectomy systems** (55%) — Devices and systems used to remove blood clots in stroke, PE, and limb ischemia. - **Neurovascular products** (20%) — Products used by specialists treating ischemic stroke and other neurovascular conditions. - **Vascular access and embolization** (15%) — Tools for accessing vessels and treating vascular abnormalities or bleeding. - **Other interventional products** (10%) — Adjunct products and newer offerings supporting the broader interventional portfolio. - Thrombectomy systems for clot removal - Computer assisted vacuum thrombectomy (CAVT) - Neurovascular stroke intervention products - Venous thromboembolism and pulmonary embolism devices - Acute limb ischemia treatment products - Embolization and vascular access technologies ## Customers Penumbra sells primarily to hospitals and healthcare systems that perform high-acuity interventional procedures. The end users are specialist physicians such as interventional neuroradiologists, neurosurgeons, interventional neurologists, interventional radiologists, interventional cardiologists, and vascular surgeons who choose these devices based on clinical performance, ease of use, and workflow efficiency. - **Hospitals and health systems** (primary) — Buy devices for use in acute care and interventional suites where clot removal procedures are performed. - **Specialist physicians** (primary) — Interventional neuroradiologists, neurologists, radiologists, cardiologists, and surgeons who use the products in procedures. - **International distributors** (secondary) — Buy and resell products in select markets where Penumbra does not sell entirely through direct teams. - **Healthcare providers in emerging end markets** (secondary) — Providers adopting thrombectomy and embolization therapies as clinical evidence and training expand. - Hospitals and health systems performing interventional procedures - Specialist physicians treating stroke, PE, and limb ischemia - Interventional neuroradiology and neurosurgery departments - Interventional cardiology and vascular surgery teams - Healthcare providers seeking faster, simpler clot-removal tools ## Geography Penumbra generates most of its revenue in the United States, with the balance coming from international markets. It sells directly in the U.S., most of Europe, Canada, Australia, and Singapore, and uses distributors in select countries, so its operating footprint is tied to both hospital adoption and regulatory access across multiple healthcare systems. - **United States** (76.8%) — Three months ended June 30, 2025 - **International** (23.2%) — Three months ended June 30, 2025 - United States is the largest revenue market - International sales are spread across Europe and other regions - Direct sales coverage in the U.S., most of Europe, Canada, Australia, and Singapore - Distributors are used in select international markets - China is an important international exposure within the broader mix ## Strategy Penumbra’s strategy centers on expanding its thrombectomy and interventional portfolio through product development, clinical evidence, and commercial expansion. It also continues to invest in manufacturing capacity, inventory, and international reach so it can support broader adoption of its devices and launch new products across target end markets. - **Expand the thrombectomy portfolio** (medium-term) — New and improved devices support adoption in stroke, PE, and limb ischemia. - **Build clinical evidence and physician adoption** (medium-term) — Specialist physicians need proof of efficacy and training before changing practice. - **Expand manufacturing and supply capacity** (short-term) — Device demand requires reliable production, inventory, and facility footprint. - **Grow international commercialization** (medium-term) — Broader geographic reach diversifies demand and extends the installed base. - Develop next-generation thrombectomy and interventional products - Use clinical evidence to expand adoption among specialist physicians - Broaden international commercial reach through direct and distributor channels - Expand manufacturing capacity and supply chain support - Invest in R&D and product iteration to refresh the portfolio ## Risks Penumbra faces competitive, regulatory, and execution risks typical of medical device companies, including reimbursement pressure, product adoption hurdles, and dependence on specialist physicians. Company-specific risks include supplier concentration, IT and ERP disruption, and uncertainty around the proposed Boston Scientific acquisition, all of which could affect operations and customer continuity. - **Supplier concentration and component shortages** [high] — Many materials and components come from a limited number of suppliers, with little guaranteed supply. - **Reimbursement and pricing pressure** [high] — Hospitals and payors may limit payment for medical devices through cost-control programs. - **Competitive intensity** [high] — Large rivals have broader product lines, deeper relationships, and more resources. - **IT and ERP implementation disruption** [medium] — System changes can interrupt order tracking, shipping, supply chain, and financial data aggregation. - **Acquisition uncertainty** [high] — Pending transaction uncertainty can affect customers, employees, and business execution. - Single-source or limited suppliers can disrupt device availability - Reimbursement pressure can limit hospital willingness to pay - Competition from larger device companies can pressure adoption - ERP and IT disruptions can affect orders, shipping, and reporting - International exposure includes China-related demand variability ## Accounting Penumbra’s accounting is shaped by revenue recognition on medical device sales, inventory and manufacturing estimates, and judgments around product development and facility investments. Investors should also watch impairment charges, especially where the company exits a business line, and estimate-driven items such as tax provisions, stock-based compensation, and any valuation assumptions tied to acquired or long-lived assets. - **Revenue recognition for product sales** — Can shift quarterly revenue and comparability - **Inventory and manufacturing estimates** — Affects gross margin and working capital - **Impairment and exit charges** — Can materially affect operating income in the period recognized - **ERP and internal control changes** — May influence cut-off, controls, and reporting reliability - Revenue recognition on device sales affects timing of reported revenue - Inventory and manufacturing estimates affect cost of revenue and margins - Impairment charges can arise when a business line is exited - ERP and systems changes can affect cut-off, shipping, and controls - Tax provisions can be volatile due to stock-based compensation and global mix --- *Last updated: 2026-04-29T04:48:10.419389+00:00*